Male breast cancer: a 5-year experience from a State Cancer Institute

Pawar, Sagar; Kumar, Manish; Kishor, Kunal; Ahmad, Nadeem; Singh, Sanjeet Kumar; Lata, Kumari Anshu

doi:10.18203/2349-2902.isj20213209

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of MBC patients in the present study was 1.3%, which was slightly higher than the worldwide average of 1%, but it is in close relation to the Indian study from Patna, Bihar by Pawar et al [ 24 ]. However, higher incidence is reported by Shah et al [ 25 ] (4.1% from Kashmir) and Khandelwal et al [ 26 ] (1.9% from Punjab).…”

Section: Discussionsupporting

confidence: 88%

Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre

Soni¹,

Verma²,

Chauhan³

et al. 2023

ecancer

View full text Add to dashboard Cite

Background Male breast cancer (MBC) is one of the rare malignancies that account for less than 1% of all malignancies in males. However, the clinicopathological characteristics of MBC are not entirely similar to female breast cancer; but still, it is treated in line with the female breast cancer protocols. Aims To retrospectively analyse trends in MBC as to its distribution, presentation, treatment, and outcome. Material and method A total of 106 patients with MBC from 1991 to 2020 were analysed retrospectively. Frequency distribution analysis of the demographic and clinicopathological data and treatment variables was done. Results Median age of presentation was 57 years; ranging from 30 to 86 years. Either of the sides was almost equally affected with an R: L ratio of 1.2:1. The average duration of complaint was 26.2 months (range 1–240 months). History of gynaecomastia was noted in 18 patients, significant benign prostate hypertrophy in 13, and hypertension needing medical treatment in 14 patients. The majority of the patients were smokers (72/106) and alcoholics (43/106). Five patients reported positive family history. 21 patients had metastatic disease at presentation and received palliative treatment. Stage II was seen in 36.8%, stage III in 43.4%, and stage IV in 19.8% of patients. Node positives were 63.2%. Pathology was invariably (90.5%) infiltrative ductal carcinoma. Radiation was administered in 85.8% of the patients, chemotherapy in 72.6% of patients, and hormonal treatment was given in 47.2% of patients. The median overall survival (OS) was 78 months. OS at 5 and 10 years was 78% and 58% respectively. Conclusion Despite the possibility of MBC being apparent at an early stage, patients present with locally advanced disease. Radical surgery with adjuvant/neoadjuvant chemotherapy and adjuvant radiotherapy remains the gold standard. Cancer education campaigns must be run to catch the early disease and to radically treat the disease.

show abstract

Section: Discussionsupporting

confidence: 88%

Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre

Soni¹,

Verma²,

Chauhan³

et al. 2023

ecancer

View full text Add to dashboard Cite

show abstract

Male Breast Cancer – Experience at a Tertiary Care Center in India

Dwivedi,

Lohia,

Nair

et al. 2023

Journal of Surgical Specialties and Rural Practice

View full text Add to dashboard Cite

Introduction: Male breast cancer (MBC) is a rare affliction accounting for approximately 1% of all breast cancer cases. The treatment guidelines of MBC mirror those of female breast cancer which are derived mostly from data obtained from studies involving female breast cancer patients. Data on MBC are mostly limited to single-institution studies due to the rarity of the disease. This study was undertaken to assess retrospectively the pattern of demographic and clinicopathological factors in MBC treated at our tertiary care center. Materials and Methods: Records of MBC treated between January 2019 and December 2020 in our institute were analyzed and data regarding the demographic and clinicopathological profile of patients was recorded. Observational retrospective single centre study. Results: A total of 12 patients of MBC were encountered with a median age of 58 years. The painless lump was the most common presentation with the retro-areolar region being the most commonly involved site. The most common American Joint Committee on Cancer anatomical stage group observed was Stage II with the left breast being involved more than the right. None of the patients had a family history of breast carcinoma. Out of the 12 patients, 10 patients were positive for hormonal receptors, whereas only two patients showed human epidermal growth factor receptor 2 amplifications. Conclusion: MBC is a rare disease. Further multi-institutional studies involving a larger number of patients are needed for a better understanding and formulation of gender-specific guidelines for the effective management of MBC.

show abstract

Male breast cancer: a 5-year experience from a State Cancer Institute

Cited by 2 publications

References 27 publications

Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre

Male breast cancer: a 30 year retrospective analysis from a tertiary cancer care centre

Male Breast Cancer – Experience at a Tertiary Care Center in India

Contact Info

Product

Resources

About